Vaccine Production in Africa: A Feasible Business Model for Capacity Building and Sustainable New Vaccine Introduction
Africa has the highest incidence of mortality caused by infectious diseases, and remarkably does not have the capacity to manufacture vaccines that are essential to reduce mortality, improving life expectancy, and promoting economic growth. GAVI has significantly helped introduction of new vaccines...
Main Authors: | Geofrey Makenga, Stefano Bonoli, Emanuele Montomoli, Trent Carrier, Joachim Auerbach |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-03-01
|
Series: | Frontiers in Public Health |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fpubh.2019.00056/full |
Similar Items
-
Egg-Independent Influenza Vaccines and Vaccine Candidates
by: Ilaria Manini, et al.
Published: (2017-07-01) -
Development of mRNA Vaccines: Scientific and Regulatory Issues
by: Ivana Knezevic, et al.
Published: (2021-01-01) -
Mechanisms of Allergen-Specific Immunotherapy and Novel Ways for Vaccine Development
by: Marek Jutel, et al.
Published: (2013-01-01) -
Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Supplement Vaccination
by: Lakshmi Jayashankar, et al.
Published: (2016-12-01) -
Impact of COVID-19 and intensive care unit capacity on vaccination support: Evidence from a two-leg representative survey in the United Kingdom
by: Géraldine Blanchard-Rohner, et al.
Published: (2021-06-01)